PATENT CLAIM ANALYSIS

Application Number: 16079588
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "04400A"]

Abstract:
The present invention relates to a novel approach for treating inflammatory disorders and other diseases, which is based on targeting ROR gamma t mRNA. The invention is directed to oligonucleotides comprising 10 to 22 modified or unmodified nucleotides complementary to specifically selected regions of the RORC, transcript variant 2 mRNA (RORC2), which codes for the ROR gamma t protein.

Claim (Index 1):
An oligonucleotide consisting of from 15 to 21 nucleotides, wherein the sequence of said oligonucleotide comprises the sequence GTGTTC, which is complementary to positions 146 to 151 of the RORC2 nucleic acid coding sequence of SEQ ID NO. 1, and wherein one or more nucleotide(s) of the oligonucleotide is/are optionally modified.

Metadata:
- Claim Count in Document: 27.0
- Percentile: 96.0
- Lexical Diversity: 1.32
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15882221', '14780043', '14779945', '14533371', '15593764']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8026257744908765
- 35 USC 102 Novelty (BERT): 0.5107412555990383
- Combined Prediction Score: 0.7734373226016927
- Mean Citation Score: 271.251044
- Max Citation Score: 285.38016
- Similarity Product: 198.5743381546784

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test